Cozad Asset Management Inc. Has $992,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

Cozad Asset Management Inc. cut its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 24.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,289 shares of the company’s stock after selling 4,609 shares during the period. Cozad Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $992,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in NVO. Strategic Investment Solutions Inc. IL grew its stake in shares of Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares during the period. Copeland Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after purchasing an additional 255 shares during the period. North Capital Inc. acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth $27,000. Park Square Financial Group LLC acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $29,000. Finally, Transce3nd LLC acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $33,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Guggenheim lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. Hsbc Global Res upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, April 28th. BMO Capital Markets reiterated a “market perform” rating and set a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Dbs Bank lowered Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. Finally, BNP Paribas assumed coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They set an “underperform” rating on the stock. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $112.00.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $53.97 on Wednesday. The firm has a market cap of $240.98 billion, a price-to-earnings ratio of 15.97, a price-to-earnings-growth ratio of 1.33 and a beta of 0.64. The stock’s 50-day moving average is $70.43 and its 200-day moving average is $73.37. Novo Nordisk A/S has a one year low of $53.51 and a one year high of $139.74. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts’ consensus estimates of $0.92. The company had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. Equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.